AI Summary
✦ ClarthaNephrocare Health Services is a dialysis healthcare provider operating kidney-care clinics and dialysis centers. In-clinic dialysis drives its core revenue, while dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels extend access across India, Uzbekistan, Nepal, and the Philippines. Revenue grew 32.9% year-on-year, but investor roadshows and approved insider share-sale plans may influence sentiment more than operations. Improving margins support earnings quality, although 14.5% profit growth trails revenue growth and ROE remains modest at 9.0%. Debt/equity of 7.14 indicates significant leverage, which can amplify ROE while increasing financial risk. At 86.7 times earnings, the shares appear rich and trade at a premium to current profit growth. The key open questions are whether margin improvement can continue and whether heavy leverage constrains expansion.
Price Forecast
Probabilistic Range
Probabilistic lognormal cone using 1Y realized volatility and analyst-target drift when available.
Revenue Forecast
₹ CrEPS Forecast
₹ / shareMulti-factor synthesis of 5 key dimensions
From 4 analysts
Fundamentals
Fundamentals institutional score is 42 using EVA spread proxy -3.0%; growth durability 59.4.
Valuation
Valuation institutional score is 40 using relative multiple z-scores where peer dispersion is available.
Analyst Consensus
Analyst View institutional score is 53 using mean target upside 9.6%; dispersion penalty 17.6; recommendation breadth from available consensus.
Technical Structure
Technicals institutional score is 75 using EMA-20 continuation within 5% tolerance; VCP range/volume contraction proxy.
Market Sentiment
Recent news flow is balanced or not decisive enough to tilt the tape. Based on 2 recent ticker-linked news items.
Signal Summary
Market intelligence remains Mixed. technical structure provide support, while fundamentals and valuation remain considerations.
Composite weights: Fundamentals 25%, Valuation 20%, Analyst Consensus 20%, Technical Structure 20%, Market Sentiment 15%.
Key Data Points
Important Note: This is market intelligence, not investment advice. Always conduct your own research and consider your financial goals and risk tolerance.
Valuation Metrics
Trading 23.7% above historical median. Valuation is rising — currently in the strongly overvalued zone (z-score: +1.43). Confidence: 87%.
Live forward EPS implies next-12-month EPS of ₹20.39. Applying the stock's normalized valuation corridor produces a fair range of ₹1,328.20 to ₹1,640.99, with base value near ₹1,415.88 (+102.9% vs current price).
Live forward estimate anchored to the company's historical valuation corridor.
Forward EPS
₹20.39
Forward P/E
34.2x
Base Fair Value
₹1,415.88
Fair Range
₹1,328.20 - ₹1,640.99
Upside To Base
+102.9%
Estimate Source
Live forward EPS
Growth Estimate
+0.1%
5Y Average
74.09
Current
85.92
Overvalued
80.48
Undervalued
65.14
5Y Average
26.81
Current
31.09
Overvalued
30.23
Undervalued
23.57
5Y Average
6.06
Current
7.02
Overvalued
6.97
Undervalued
5.15
Peers & Comparison
Sector: Health Care · Theme: Hospitals & Diagnostic Centres
| Company | Rev. Growth | Margin | P/E | vs Avg | 52W Perf. |
|---|---|---|---|---|---|
METROPOLIS HEALTHCARE LTD METROPOLISHospitals & Diagnostic Centres | +16.6% | 11.8% | 58.9x Undervalued | -16% vs avg | +7.6% |
VIJAYA DIAGNOSTIC CEN LTD VIJAYAHospitals & Diagnostic Centres | +26.6% | 21.2% | 83.0x Premium | +18% vs avg | +28.0% |
PARK MEDI WORLD LIMITED PARKHOSPSHospitals & Diagnostic Centres | +19.3% | 16.1% | 45.7x Undervalued | -35% vs avg | +95.4% |
JUPITER LIFE LINE HOSP L JLHLHospitals & Diagnostic Centres | +18.2% | 12.0% | 55.6x Undervalued | -21% vs avg | +12.9% |
THYROCARE TECH LTD THYROCAREHospitals & Diagnostic Centres | +24.3% | 20.1% | 54.8x Undervalued | -22% vs avg | +38.2% |
YATHARTH HOSP & TRA C S L YATHARTHHospitals & Diagnostic Centres | +44.2% | 14.2% | 50.0x Undervalued | -29% vs avg | +23.8% |
KRISHNA INST OF MED SCI L KIMSHospitals & Diagnostic Centres | +35.3% | 4.8% | 159.7x Premium | +127% vs avg | +10.2% |
RAINBOW CHILDRENS MED LTD RAINBOWHospitals & Diagnostic Centres | +33.2% | 15.7% | 54.4x Undervalued | -23% vs avg | +1.2% |
NEPHROCARE HEALTH SERV L trades at a premium (86.9x vs peer avg 70.3x), implying higher growth or quality expectations from the Hospitals & Diagnostic Centres cohort. Peers include METROPOLIS HEALTHCARE LTD, VIJAYA DIAGNOSTIC CEN LTD, PARK MEDI WORLD LIMITED — selected based on business model, industry classification, market cap similarity, and business theme alignment.
Financials
Real statement data for revenue, earnings quality, conversion, and balance-sheet coverage. Monetary values are shown in Rs crore.
Latest revenue
₹164 CrMar 2026Latest net profit
₹11 CrMar 2026Latest EPS
₹1.09Mar 2026Net margin
13.0%Mar 2026Performance
Bars show revenue and net profit. The line shows net margin.
- Revenue
- Net income
- Net margin %
Earnings
Revenue is shown in crores. EPS is rupees per share.
- Revenue
- EPS
Revenue to profit conversion
Bridge from operating numbers to profit for the latest reported period.
Latest reported period: Mar 2026
Debt level and coverage
Debt, cash and free cash flow compared on the same crore scale.
- Debt
- Free cash flow
- Cash & equivalents
Results
| Metric | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales + | 138 | 145 | 156 | 161 | 164 |
| Expenses + | 116 | 123 | 132 | 138 | 142 |
| Operating Profit | 22 | 22 | 23 | 23 | 22 |
| OPM % | 16% | 15% | 15% | 14% | 13% |
| Other Income + | 4 | 3 | 3 | 3 | 6 |
| Interest | 3 | 4 | 41 | 4 | 1 |
| Depreciation | 12 | 13 | 16 | 13 | 16 |
| Profit before tax | 11 | 7 | -31 | 9 | 11 |
| Tax % | 25% | 24% | 6% | 6% | 1% |
| Net Profit + | 8 | 6 | -32 | 8 | 11 |
| EPS in Rs | 38.97 | 27.20 | -17.92 | 0.84 | 1.09 |
| Raw PDF |
All values in ₹ Crores unless otherwise stated. Source: Screener Master (Standalone).
Events Timeline
Announcement under Regulation 30 (LODR)-Trading Plan under SEBI (PIT) Regulations, 2015
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Board Meeting Intimation for The Company Has Informed BSE That The Meeting Of The Board Is Scheduled On 11/08/2026 ,Inter Alia, To Consider And Approve The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2026.